文献速递淋巴瘤

FCR方案一线治疗CLL/SLL的疗效与长期随访报告

[Efficacy and long-term follow-up report of FCR regimen in the first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2025-01-01

该研究回顾性分析68例接受FCR方案一线治疗的CLL/SLL患者,总反应率88.2%,完全缓解率47.0%,中位随访82个月,中位PFS 56个月,中位OS未达到;IGHV-M且无del(17p)及复杂核型患者5年PFS率70.7%且5年后达平台期。

要点

  • FCR一线治疗CLL/SLL总反应率88.2%,完全缓解率47.0%。
  • IGHV-M且无del(17p)及复杂核型者5年PFS率70.7%,5年后达平台期。
  • IGHV无突变为PFS独立预后因素(HR=8.63)。

核心结论

  • FCR方案一线治疗可使IGHV-M且无del(17p)及复杂核型的CLL/SLL患者获得长期获益。

研究设计与样本

  • 回顾性分析2008年8月至2021年5月江苏省人民医院血液科68例接受FCR一线治疗的CLL/SLL患者。

主要发现

  • 总反应率88.2%(60/68),完全缓解率47.0%(32/68)。
  • 中位随访82(59,98)个月,66.2%(45/68)出现疾病进展,中位PFS 56(21,123)个月,中位OS未达到。
  • 5年和10年PFS率分别为42.6%(95%CI:31.9%~56.8%)和28.7%(95%CI:19.0%~43.4%)。
  • 16例IGHV-M且无del(17p)及CK患者中位PFS 123(58,123)个月,5年PFS率70.7%(95%CI:49.7%~99.1%),5年后达平台期,10年内无复发。
  • 25例进展后接受BTK抑制剂单药治疗,中位随访45(26,64)个月,36%(9/25)出现疾病进展,中位PFS 55(27,55)个月。

关键数值与推荐

  • del(17p) HR=5.04(95%CI:1.72~14.74,P=0.003);del(11q) HR=5.27(95%CI:2.11~13.15,P<0.001)。
  • IGHV无突变 HR=4.11(95%CI:1.72~9.79,P=0.001);复杂核型 HR=3.53(95%CI:1.58~7.85,P=0.002)。
  • β2微球蛋白>3.5 mg/L HR=2.87(95%CI:1.37~6.01,P=0.005)。
  • 多因素分析IGHV无突变为PFS独立预后因素(HR=8.63,95%CI:1.09~68.40,P=0.042)。
  • 3~4级不良反应:血液学毒性44.1%(30/68),感染36.7%(25/68),肝功能受损4.4%(3/68)。

临床怎么用

  • 对IGHV-M且无del(17p)及复杂核型的CLL/SLL患者,一线FCR方案可带来持久长期获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the efficacy and long-term outcomes of fludarabine, cyclophosphamide, and rituximab (FCR) in treatment-naïve patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) . Methods: Clinical data from 68 CLL/SLL patients treated with FCR at Jiangsu Province Hospital (August 2008-May 2021) were retrospectively analyzed to assess efficacy, safety, and survival outcomes. Results: Among 68 patients [46 males, 22 females; median age 55 (47, 60) years], 13.1% (8/61) had a complex karyotype, 32.3% (20/62) had immunoglobulin heavy variable region mutated (IGHV-M) type, 6.6% (4/61) had del (17p), and 14.8% (8/54) had del (11q). Patients received a median of 6 (4, 6) FCR cycles. The overall response rate was 88.2% (60/68), including 47.0% (32/68) complete remissions. Over a median follow-up of 82 (59, 98) months, 66.2% (45/68) experienced disease progression. Median progression-free survival was 56 (21, 123) months, while median overall survival was not reached. The 5- and 10-year PFS rates were 42.6% (95% CI: 31.9-56.8% ) and 28.7% (95% CI: 19.0-43.4% ), respectively. Poor PFS was associated with del (17p) (HR=5.04, 95% CI: 1.72-14.74, P=0.003), del (11q) (HR=5.27, 95% CI: 2.11-13.15, P<0.001), IGHV unmutated (IGHV-UM) (HR=4.11, 95% CI: 1.72-9.79, P=0.001), complex karyotype (CK) (HR=3.53, 95% CI: 1.58-7.85, P=0.002), β(2)-microglobulin >3.5 mg/L (HR=2.87, 95% CI: 1.37-6.01, P=0.005). In multivariate analysis, IGHV-UM remained an independent predictor of PFS (HR=8.63, 95% CI: 1.09-68.40, P=0.042). Sixteen patients with IGHV-M and lacking del (17p) or CK had a median PFS of 123 (58,123) months and a 5-year PFS rate of 70.7% (95% CI: 49.7-99.1% ), reaching a plateau after 5 years with no recurrences by 10 years. Common grade 3-4 adverse events included hematologic toxicity (44.1%, 30/68), infection (36.7%, 25/68), and liver dysfunction (4.4%, 3/68). Among 25 patients receiving single-agent BTK inhibitors after FCR progression, median follow-up was 45 (26, 64) months; 36% (9/25) experienced disease progression, with a median PFS time of 55 (27, 55) months. Conclusion: First-line FCR provides durable long-term benefits for patients with IGHV-M CLL without del (17p) or CK. 目的: 探讨FCR(氟达拉滨+环磷酰胺+利妥昔单抗)方案一线治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤(CLL/SLL)的疗效、影响因素及长期随访结果。 方法: 回顾性分析2008年8月至2021年5月期间于江苏省人民医院血液科接受FCR方案一线治疗的68例CLL/SLL患者的疗效、安全性及长期随访结局。 结果: 68例患者中女22例、男46例,接受FCR方案治疗时中位年龄为55(47,60)岁。复杂核型(CK)8例(13.1%,8/61),免疫球蛋白重链可变区突变(IGHV-M)20例(32.3%,20/62),del(17p)4例(6.6%,4/61),del(11q)8例(14.8%,8/54)。患者接受FCR方案治疗的中位疗程数为6(4,6)个。患者总反应率为88.2%(60/68),完全缓解率为47.0%(32/68)。中位随访时间为82(59,98)个月,66.2%(45/68)患者出现疾病进展,中位无进展生存(PFS)期为56(21,123)个月,中位总生存期未达到。5年和10年PFS率分别为42.6%(95% CI:31.9%~56.8%)和28.7%(95% CI:19.0%~43.4%)。del(17p)(HR=5.04,95% CI:1.72~14.74,P=0.003)、del(11q)(HR=5.27,95% CI:2.11~13.15,P<0.001)、IGHV无突变(HR=4.11,95% CI:1.72~9.79,P=0.001)、CK(HR=3.53,95% CI:1.58~7.85,P=0.002)、β(2)微球蛋白>3.5 mg/L(HR=2.87,95% CI:1.37~6.01,P=0.005)为PFS的不良预后因素,多因素分析显示IGHV无突变为PFS的独立预后因素(HR=8.63,95% CI:1.09~68.40,P=0.042)。16例IGHV-M且无del(17p)及CK的患者中位PFS期达123(58,123)个月,5年PFS率为70.7%(95% CI:49.7%~99.1%),5年后到达PFS平台期,10年内无复发。常见的3~4级不良反应:血液学不良反应(44.1%,30/68),感染(36.7%,25/68),肝功能受损(4.4%,3/68)。25例(56.8%,25/44)患者疾病进展后接受布鲁顿酪氨酸激酶抑制剂单药治疗,中位随访时间为45(26,64)个月,36%(9/25)患者出现疾病进展,中位PFS期为55(27,55)个月。 结论: FCR方案一线治疗可以使IGHV-M且无del(17p)及CK的CLL/SLL患者长期获益。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Lu X, Xia Y, Miao Y, et al. [Efficacy and long-term follow-up report of FCR regimen in the first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma]. Zhonghua Xue Ye Xue Za Zhi. 2025. PMID: 41407461. doi:10.3760/cma.j.cn121090-20250107-00013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。